Featured Research

from universities, journals, and other organizations

FDA approves new MS treatment regimen

Date:
January 30, 2014
Source:
Wayne State University Division of Research
Summary:
Recent research has led to a new treatment regimen that will affect millions of multiple sclerosis patients around the world. The U.S. Food and Drug Administration has approved a new drug application that calls for the injection of Copaxone at a higher dose, but fewer times per week for patients with relapsing forms of multiple sclerosis.

Global research overseen by and conducted at the Wayne State University School of Medicine will immediately change the treatment regimen of millions of multiple sclerosis patients around the world.

The U.S. Food and Drug Administration Tuesday approved a new drug application that calls for the injection of Copaxone at a higher dose, but fewer times per week for patients with relapsing forms of multiple sclerosis.

"The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for patients as they now have the option of effective and safe treatment with the drug, while reducing the number of injections by 60 percent," said Omar Khan, M.D., professor and chair of neurology at the Wayne State University School of Medicine. "Patients in the United States can now benefit from an improved dosing regimen without compromising the known benefits of Copaxone." The study was published in the Annals of Neurology, a leading clinical neuroscience journal and the official publication of the American Neurological Association.

Dr. Khan, a member of the Wayne State University Physician Group, is the global principal investigator of the Glatiramer Acetate Low-Frequency Administration, or GALA, study. The study investigated a new dose and frequency of glatiramer acetate (Copaxone) in patients with relapsing remitting multiple sclerosis. The study demonstrated that glatiramer acetate given in 40 mg doses subcutaneously three times a week is at least as effective as daily injections in achieving the drug's immunologic effect and therapeutic efficacy.

The FDA approval is based on data from the Phase III GALA study of more than 1,400 patients, which showed that the higher dose injected three times a week significantly reduced relapse rates at 12 months and demonstrated a favorable safety and tolerability profile in patients with relapsing remitting MS.

Glatiramer acetate, commercially known as Copaxone and produced by Teva Pharmaceuticals, had been approved by the FDA for the treatment of relapsing forms of MS at a dose of 20 mg subcutaneously daily. It is the most prescribed medication for the treatment of MS, with annual worldwide sales exceeding $3.5 billion.

Medical experts estimate that more 2 million people in the world, more than 500,000 in the U.S., 30,000 in Michigan and 16,000 in metropolitan Detroit have MS. The Wayne State University MS Center is considered amongst the five largest MS centers in the country, with more than 4,000 patients.

"This study provides confirmation of a concept that originated at Wayne State University and will impact the entire field, including patients worldwide," Dr. Khan said. "I take great pride in the fact that work done at Wayne State University led to this large international study, not only confirming our original work but changing the lives of people with MS in the world. This is truly translational work involving optimization of a peptide therapy without compromising its immunomodulating effect. For patients, it is great news, as reduced frequency of injections will improve compliance and tolerability while maintaining efficacy."

Teva officials said the three-times-a-week Copaxone dose is available for shipping to distribution outlets immediately, and will be available to patients within days. The drug is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel and all European countries.


Story Source:

The above story is based on materials provided by Wayne State University Division of Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Omar Khan, Peter Rieckmann, Alexey Boyko, Krzysztof Selmaj, Robert Zivadinov. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology, 2013; 73 (6): 705 DOI: 10.1002/ana.23938

Cite This Page:

Wayne State University Division of Research. "FDA approves new MS treatment regimen." ScienceDaily. ScienceDaily, 30 January 2014. <www.sciencedaily.com/releases/2014/01/140130133045.htm>.
Wayne State University Division of Research. (2014, January 30). FDA approves new MS treatment regimen. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2014/01/140130133045.htm
Wayne State University Division of Research. "FDA approves new MS treatment regimen." ScienceDaily. www.sciencedaily.com/releases/2014/01/140130133045.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins